RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-14.25%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.67B
AUM Growth
+$5.67B
(-21%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8
Top Buys
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$82.4M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$55.9M |
| 3 |
LIAN
LianBio American Depositary Shares
LIAN
|
$47.2M |
| 4 |
Relmada Therapeutics
RLMD
|
$45.1M |
| 5 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
$34.8M |
Top Sells
| 1 |
Atea Pharmaceuticals
AVIR
|
$190M |
| 2 |
TG Therapeutics
TGTX
|
$35.9M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$21M |
| 4 |
CytomX Therapeutics
CTMX
|
$17.8M |
| 5 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$10.2M |
Sector Composition
| 1 | Healthcare | 98.88% |
| 2 | Financials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Ocular Therapeutix
OCUL
$2.25B
| – | – |
-750,000
| Closed | -$7.5M |
|
102
Viridian Therapeutics
VRDN
$1.59B
| – | – |
-1,034
| Closed | -$17K |
|
|
OKUR
103
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| – | – |
-6,222
| Closed | -$464K |
|
|
WHWK
104
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| – | – |
-347,668
| Closed | -$10.2M |
|
|
CCXI
105
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-218,532
| Closed | -$3.74M |
|